LYVA Labs is taking the lead in investing in under-served founders and CEOs. This week, the company backed its fourth female-led business, Spotlight Pathology, with £125k from its health and life sciences pre-seed fund.
LYVA Labs was set up with 11M from Liverpool City Region’s Combined Authority as an innovation commercialisation company to turn great ideas into high-growth businesses and quality jobs. LYVA Labs’ funding will enable Spotlight Pathology to accelerate product development and commercialisation.
Spotlight is developing AI tools to support pathologists to make complex blood cancer diagnoses. There is a global shortage of highly trained pathologists, resulting in significant pressures on the system and pressures on pathologists that can lead to delays in diagnoses. CEO Dr Sam Perona recently joined co-founders Dr Martin Fergie and Prof Richard Byers to lead the business to commercial success.
CEO of LYVA Labs, Lorna Green, is dedicated to untapping the potential of ambitious female entrepreneurs. She chairs Liverpool City Region’s new Female Founder Regional HIGH Growth Board, set up as part of the Lifted Project, a data and ecosystem-led approach to increasing the flow of capital to regional, high-growth female founders. Dr Sam Perona joined Spotlight Pathology as CEO, after a successful exit from her own business Perfectus Biomed and has joined the regional board as a member, role model and mentor for other regional female founders.
More about Spotlight Pathology: Sci-tech Daresbury-based Spotlight Pathology has secured £125,000 investment from LYVA Labs’ Health and Life Sciences Fund. Spotlight was spun out of the University of Manchester in January 2020 by Dr Martin Fergie and Prof Richard Byers and recently re-located to Daresbury. Spotlight has developed AI tools to streamline the diagnosis process for blood cancer representing a $15b global market opportunity. Diagnosis is time-consuming due to the shortage of highly trained pathologists which results in delayed diagnoses, treatment, and poor patient outcomes. Spotlight is already in receipt of a £0.9m Innovate UK grant, which has allowed it to build up a significant data bank of blood tissue samples and recruit Dr Sam Perona as CEO in April 2024, following her successful exit of Perfectus Biomed, which she grew from a start-up.
Dr Sam Perona, CEO of Spotlight Pathology, said, “We are delighted to receive this investment from LYVA labs. The investment process was rapid and straightforward, allowing us to focus on developing the business. This investment will allow us to grow the team and accelerate our ‘go to market’ plan. “
Akshay Bhatnagar, Head of Investment, LYVA Labs, said: “LYVA Labs is delighted to back Sam, Martin, and Richard in their mission to help reduce the number of people dying from blood cancer by providing the technology to allow more rapid diagnoses, which will enable earlier treatment for the condition. We look forward to working with the team and seeing the product come to market over the next 12 months.”
